Find Sobuzoxane manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 98631-95-9, Mst 16, Mst-16, [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate, Perazolin, R1308vh37p
Molecular Formula
C22H34N4O10
Molecular Weight
514.5  g/mol
InChI Key
OCOKWVBYZHBHLU-UHFFFAOYSA-N
FDA UNII
R1308VH37P

Sobuzoxane
Sobuzoxane is the orally available active prodrug of ICRF-154, a bisdioxopiperazine derivative, with cardioprotective and antineoplastic activities. Like other ICRF compounds, sobuzoxane and its active metabolite ICRF-154 interfere with topoisomerase II activity prior to the formation of intermediate cleavable DNA-enzyme complexes during the catalytic cycle resulting in tumor cell growth inhibition. Furthermore, sobuzoxane chelates metal cations thereby limiting the formation of free radical-generating anthracycline-metal complexes and may prevent anthracycline-induced oxidative damage to cardiac and soft tissues.
1 2D Structure

Sobuzoxane

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate
2.1.2 InChI
InChI=1S/C22H34N4O10/c1-15(2)11-33-21(31)35-13-25-17(27)7-23(8-18(25)28)5-6-24-9-19(29)26(20(30)10-24)14-36-22(32)34-12-16(3)4/h15-16H,5-14H2,1-4H3
2.1.3 InChI Key
OCOKWVBYZHBHLU-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)COC(=O)OCN1C(=O)CN(CC1=O)CCN2CC(=O)N(C(=O)C2)COC(=O)OCC(C)C
2.2 Other Identifiers
2.2.1 UNII
R1308VH37P
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1,2-bis(4-isobutoxycarbonyloxymethyl-3,5-dioxopiperazin-1-yl)ethane

2. Mst 16

3. Mst-16

2.3.2 Depositor-Supplied Synonyms

1. 98631-95-9

2. Mst 16

3. Mst-16

4. [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl Carbonate

5. Perazolin

6. R1308vh37p

7. Sobuzoxane (jan)

8. Ncgc00015954-02

9. Sobuzoxane [jan]

10. Sobuzoxano

11. Sobuzoxanum

12. Sobuzoxane [inn:jan]

13. Sobuzoxanum [inn-latin]

14. 4,4'-(1,2-ethanediyl)bis(1-iso-butoxycarbonyloxmethyl-2,6-piperazinedione)

15. Sobuzoxano [inn-spanish]

16. Brn 6031322

17. Unii-r1308vh37p

18. Perazolin (tn)

19. Sobuzoxane [mi]

20. Sobuzoxane [inn]

21. Lopac-s-4692

22. 1,2-bis(4-isobutoxycarbonyloxymethyl-3,5-dioxo-piperazin-1-yl)ethane

23. Sobuzoxane [mart.]

24. 4,4'-ethylenebis(1-(hydroxymethyl)-2,6-piperazinedione) Bis(isobutyl Carbonate) (ester)

25. Dsstox_cid_25203

26. Dsstox_rid_80747

27. Sobuzoxane [who-dd]

28. Dsstox_gsid_45203

29. Lopac0_001094

30. Schembl18416

31. Mls002153414

32. Chembl1256871

33. Dtxsid5045203

34. Chebi:32136

35. Hms2230c04

36. Hms3263k10

37. Hms3369l07

38. Tox21_110265

39. Tox21_501094

40. Mfcd00866498

41. Zinc22032147

42. Sobuzoxane, >=99% (hplc), Solid

43. Ccg-205171

44. Lp01094

45. Sdccgsbi-0051064.p002

46. Ncgc00015954-01

47. Ncgc00015954-03

48. Ncgc00015954-04

49. Ncgc00094367-01

50. Ncgc00094367-02

51. Ncgc00261779-01

52. Carbonic Acid, 1,2-ethanediylbis((2,6-dioxo-4,1-piperazinediyl)methylene)bis(2-methylpropyl) Ester

53. Smr001230790

54. Cas-98631-95-9

55. Eu-0101094

56. 1-n-trityl-imidazole-2-ylpropionicacid

57. D01404

58. F52515

59. S 4692

60. 631s959

61. A839107

62. Sr-01000075401

63. Sr-01000075401-2

64. Q27287640

65. 4,4'-(1,2-ethanediyl)bis(1-isobutoxycarbonyloxmethyl-2,6-piperazinedione)

66. 4,4'-(1,2-ethanediyl)bis(1-isobutoxycarbonyloxymethyl-2,6-piperazinedione)

67. (4,4'-(ethane-1,2-diyl)bis(2,6-dioxopiperazine-4,1-diyl))bis(methylene) Isobutyl Dicarbonate

68. [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-bis(oxidanylidene)piperazin-1-yl]ethyl]-2,6-bis(oxidanylidene)piperazin-1-yl]methyl 2-methylpropyl Carbonate

69. [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxo-piperazin-1-yl]ethyl]-2,6-dioxo-piperazin-1-yl]methyl 2-methylpropyl Carbonate

70. Carbonic Acid [4-[2-[4-[[2-methylpropoxy(oxo)methoxy]methyl]-3,5-dioxo-1-piperazinyl]ethyl]-2,6-dioxo-1-piperazinyl]methyl 2-methylpropyl Ester

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 514.5 g/mol
Molecular Formula C22H34N4O10
XLogP32
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count12
Rotatable Bond Count15
Exact Mass514.22749329 g/mol
Monoisotopic Mass514.22749329 g/mol
Topological Polar Surface Area152 Ų
Heavy Atom Count36
Formal Charge0
Complexity743
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Topoisomerase II Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty